Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research

(Dec 15, 2025) by Reuters.

Adaptive said it will earn up to $890 million for the rheumatoid arthritis asset, including upfront fees and milestone payments tied to research progress, product development, and sales.

Pfizer will use Adaptive’s technology to analyze immune cells from rheumatoid arthritis patients and hunt for T-cell receptors, which are proteins on immune cells that act like scanners spotting disease triggers.

Adaptive will work on early detection, with Pfizer focusing on later development and commercialization, as per the agreement.